Anti-NGF drugs [58] and angiogenesis inhibitors (http://www.cancer.gov/cancertopics/factsheet/Therapy/angiogenesis-inhibitors) [64] are being developed by cancer researchers and are primarily intended for treatment of neoplastic diseases, but some of these agents may also find applications in other areas of medicine including rheumatology. Here, NGF is linked to neoplasm.